These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25823785)

  • 1. FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis.
    Dávila-Fajardo CL; van der Straaten T; Baak-Pablo R; Medarde Caballero C; Cabeza Barrera J; Huizinga TW; Guchelaar HJ; Swen JJ
    Pharmacogenomics; 2015; 16(4):373-81. PubMed ID: 25823785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors.
    Montes A; Perez-Pampin E; Joven B; Carreira P; Fernández-Nebro A; Del Carmen Ordóñez M; Navarro-Sarabia F; Moreira V; Vasilopoulos Y; Sarafidou T; Caliz R; Ferrer MA; Cañete JD; de la Serna AR; Magallares B; Narváez J; Gómez-Reino JJ; Gonzalez A
    Pharmacogenomics; 2015; 16(4):333-45. PubMed ID: 25823782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis.
    Jiménez Morales A; Maldonado-Montoro M; Martínez de la Plata JE; Pérez Ramírez C; Daddaoua A; Alarcón Payer C; Expósito Ruiz M; García Collado C
    J Clin Pharmacol; 2019 Apr; 59(4):517-531. PubMed ID: 30457672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis.
    Montes A; Perez-Pampin E; Narváez J; Cañete JD; Navarro-Sarabia F; Moreira V; Fernández-Nebro A; Del Carmen Ordóñez M; de la Serna AR; Magallares B; Vasilopoulos Y; Sarafidou T; Caliz R; Ferrer MA; Joven B; Carreira P; Gómez-Reino JJ; Gonzalez A
    Pharmacogenet Genomics; 2014 May; 24(5):238-45. PubMed ID: 24667440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC
    Rheumatol Int; 2016 Jun; 36(6):837-44. PubMed ID: 27074847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup.
    Ramírez J; Fernández-Sueiro JL; López-Mejías R; Montilla C; Arias M; Moll C; Alsina M; Sanmarti R; Lozano F; Cañete JD
    J Rheumatol; 2012 May; 39(5):1035-41. PubMed ID: 22467926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
    Dávila-Fajardo CL; Márquez A; Pascual-Salcedo D; Moreno Ramos MJ; García-Portales R; Magro C; Alegre-Sancho JJ; Balsa A; Cabeza-Barrera J; Raya E; Martín J
    Pharmacogenet Genomics; 2014 Jan; 24(1):1-5. PubMed ID: 24253594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.
    Krieckaert CL; Jamnitski A; Nurmohamed MT; Kostense PJ; Boers M; Wolbink G
    Arthritis Rheum; 2012 Dec; 64(12):3850-5. PubMed ID: 22933315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
    Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
    Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.
    Quartuccio L; Fabris M; Pontarini E; Salvin S; Zabotti A; Benucci M; Manfredi M; Biasi D; Ravagnani V; Atzeni F; Sarzi-Puttini P; Morassi P; Fischetti F; Tomietto P; Bazzichi L; Saracco M; Pellerito R; Cimmino M; Schiavon F; Carraro V; Semeraro A; Caporali R; Cavagna L; Bortolotti R; Paolazzi G; Govoni M; Bombardieri S; De Vita S
    Ann Rheum Dis; 2014 Apr; 73(4):716-21. PubMed ID: 23505228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FCGR2A, FCGR3A, FCGR3B polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC; Song GG
    Clin Exp Rheumatol; 2015; 33(5):647-54. PubMed ID: 26314337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab.
    Ruyssen-Witrand A; Rouanet S; Combe B; Dougados M; Le Loët X; Sibilia J; Tebib J; Mariette X; Constantin A
    Ann Rheum Dis; 2012 Jun; 71(6):875-7. PubMed ID: 22368231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of FCGR2A R131H, FCGR3A F158V and FCGR3B NA1/NA2 polymorphisms on response to Fc-containing TNF inhibitors in Tunisian rheumatoid arthritis patients.
    Mahmoud I; Moalla M; Ben Tekaya A; Bouden S; Rouached L; Tekaya R; Saidane O; Gorji Y; Elleuch M; Laatar A; Hamdi W; Abdelmoula L; Sfar I
    Drug Metab Pers Ther; 2023 Jun; 38(2):155-162. PubMed ID: 36919284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis.
    Eektimmerman F; Swen JJ; Böhringer S; Huizinga TW; Kooloos WM; Allaart CF; Guchelaar HJ
    Pharmacogenomics; 2017 Jul; 18(10):945-953. PubMed ID: 28639493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis.
    Avila-Pedretti G; Tornero J; Fernández-Nebro A; Blanco F; González-Alvaro I; Cañete JD; Maymó J; Alperiz M; Fernández-Gutiérrez B; Olivé A; Corominas H; Erra A; Aterido A; López Lasanta M; Tortosa R; Julià A; Marsal S
    PLoS One; 2015; 10(4):e0122088. PubMed ID: 25848939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy.
    Cui J; Saevarsdottir S; Thomson B; Padyukov L; van der Helm-van Mil AH; Nititham J; Hughes LB; de Vries N; Raychaudhuri S; Alfredsson L; Askling J; Wedrén S; Ding B; Guiducci C; Wolbink GJ; Crusius JB; van der Horst-Bruinsma IE; Herenius M; Weinblatt ME; Shadick NA; Worthington J; Batliwalla F; Kern M; Morgan AW; Wilson AG; Isaacs JD; Hyrich K; Seldin MF; Moreland LW; Behrens TW; Allaart CF; Criswell LA; Huizinga TW; Tak PP; Bridges SL; Toes RE; Barton A; Klareskog L; Gregersen PK; Karlson EW; Plenge RM
    Arthritis Rheum; 2010 Jul; 62(7):1849-61. PubMed ID: 20309874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta-analysis.
    Lee YH; Song GG
    Int J Rheum Dis; 2023 Jul; 26(7):1295-1304. PubMed ID: 37114884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.